Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Thomas Permutt"'
Autor:
Thomas Permutt
Publikováno v:
Statistics in Biopharmaceutical Research. 12:45-53
Adjustment for covariates has been underused in trials intended to support approval of medical products. This underuse results partly from confusion about whether adjusting changes the thin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09c683f341e831a83e10a6ea83751f9f
https://doi.org/10.1080/19466315.2019.1647874
https://doi.org/10.1080/19466315.2019.1647874
Autor:
Thomas Permutt
Publikováno v:
Statistics in Biopharmaceutical Research. 12:137-141
The causal estimands of interest in a clinical trial are treatment effects, and a treatment effect is a comparison of the outcomes for the same patients, or for similar groups of patients, on diffe...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::195653a3197feaef92263fc165acabc6
https://doi.org/10.1080/19466315.2019.1624192
https://doi.org/10.1080/19466315.2019.1624192
Autor:
Stephen J. Ruberg, William H. Crown, Jodi B Segal, Thomas Permutt, Thomas A. Louis, John Scott, Mark Rothmann
Publikováno v:
Pharmaceutical statisticsREFERENCES. 20(5)
Clinical trials are primarily conducted to understand the average effects treatments have on patients. However, patients are heterogeneous in the severity of the condition and in ways that affect what treatment effect they can expect. It is therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9faa20afe0749b88184c2829ad1735e9
https://pubmed.ncbi.nlm.nih.gov/33118319
https://pubmed.ncbi.nlm.nih.gov/33118319
Autor:
Lisa M. LaVange, Julia A. Beaver, Robert N. Schuck, Christopher Leptak, Janet Woodcock, Steven Lemery, Rosane Charlab, Issam Zineh, Peter Stein, Hobart Rogers, Michael Pacanowski, E. David Litwack, Badrul A. Chowdhury, Gideon M. Blumenthal, Jonathan P. Jarow, Robert Temple, Thomas Permutt, Sarah E. Dorff
Publikováno v:
Clinical Pharmacology & Therapeutics. 104:282-289
Advances in our understanding of the molecular underpinnings of disease have spurred the development of targeted therapies and the use of precision medicine approaches in patient care. While targeted therapies have improved our capability to provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a6589b9687412cdbb7fb9d43c369a2
https://doi.org/10.1002/cpt.1041
https://doi.org/10.1002/cpt.1041
Publikováno v:
Pharmaceutical Statistics. 16:378-392
In some randomized (drug versus placebo) clinical trials, the estimand of interest is the between-treatment difference in population means of a clinical endpoint that is free from the confounding effects of "rescue" medication (e.g., HbA1c change fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc6b883717f407361e6c32fa61dbf67
https://doi.org/10.1002/pst.1817
https://doi.org/10.1002/pst.1817
Autor:
Thomas Permutt
Publikováno v:
Statistics in Biopharmaceutical Research. 10:233-235
Dropouts confound the treatment effect when the outcome and the dropout process both depend on subject characteristics. If dropout is unrelated to treatment, there is an unconfounded effect, but it...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e268e1723c03e7b6101f13071998735
https://doi.org/10.1080/19466315.2018.1458650
https://doi.org/10.1080/19466315.2018.1458650
Autor:
Thomas Permutt
Publikováno v:
Clinical trials (London, England). 16(4)
The proposed addendum to the International Conference on Harmonization document, Statistical Principles for Clinical Trials, can be read in two ways. There is a new framework for talking about estimands, but is it about fitting present methods into t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0535559c8637321b0df5eaa837e6ce6
https://pubmed.ncbi.nlm.nih.gov/30764658
https://pubmed.ncbi.nlm.nih.gov/30764658
Autor:
Feng Li, Thomas Permutt
Publikováno v:
Pharmaceutical Statistics. 16:20-28
Dropouts from randomized trials, often for lack of efficacy or toxicity, have usually been handled as 'missing data'. We suggest that they are instead complete observations, just not numeric ones. We propose an exact test of the hypothesis of no drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9ff9aa30d83028e3531b0d2fb88b547
https://doi.org/10.1002/pst.1768
https://doi.org/10.1002/pst.1768
Autor:
Thomas Permutt, Lisa M. LaVange
Publikováno v:
Statistics in Medicine. 35:2853-2864
The issuance of a report in 2010 by the National Research Council (NRC) of the National Academy of Sciences entitled 'The Prevention and Treatment of Missing Data in Clinical Trials,' commissioned by the US Food and Drug Administration, had an immedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9f542da4537dcc9c722caa2585293bc
https://doi.org/10.1002/sim.6840
https://doi.org/10.1002/sim.6840
Autor:
Thomas Permutt
Publikováno v:
Clinical pharmacology and therapeutics. 105(4)
It would often be of interest to know the effect of a drug compared to control in people who take the drug. However, different people will likely take the drug and the control. Thus, comparing takers of the drug to takers of the control does not yiel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa3d5aa9cab4e7a3490939275360c25
https://pubmed.ncbi.nlm.nih.gov/30471237
https://pubmed.ncbi.nlm.nih.gov/30471237